A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Phase: PHASE2
Conditions: Non Small Cell Lung Cancer Metastatic
Sponsor: Transgene

transgene
SPONSOR: 
Clinical Study Protocol 
CONFIDENTIAL 
A phase II study evaluating the efficacy and the safety of first-line chemotherapy 
combined with TG4010 and nivolumab in patients with advanced non-squamous 
Non-Small-Cell Lung Cancer (NSCLC) 
Study phase: II 
PROTOCOL N° TG4010.24 
Amended Version 4.0 - 13 March 2018 
EUDRACT N° 2016-005115-41 
IND N° 8559 
NCT03353675 
Transgene S.A. 
Boulevard Gonthier d'Andernach 
Parc d'innovation - CS80166 
67405 Illkirch Graffenstaden Cedex - FRANCE 
The confidential infonnation contained in this document is the property ofTransgene. lt is provided to you in confidence, for review by you, 
your staff, regulatory authorities, and members of ethics committees or institutional review boards. lt is understood that this information will 
not be disclosed to any other third party, in any form, without prior authorization from Transgene, except to the extent necessary to obtain the 
written informed consent from the persons to whom the lnvestigalional Medicinal Product may be administered.